Code assignment supports billing clarity and claims reporting for Imbed’s synthetic antimicrobial wound matrix with localized, non-opioid pain management MIDDLETON, Wis., April 1, 2026 /PRNewswire/ — Imbed Biosciences today announced that the Centers for
Read More from Imbed Biosciences Announces CMS Assignment of HCPCS Code A2040 for Microlyte® PainGuard™
Imbed Biosciences Launches Dual-Action Wound Matrix Integrating Bioburden Management and Pain Relief in a Single Solution
MIDDLETON, Wis., Aug. 28, 2025 /PRNewswire/ — Imbed Biosciences Inc., a leader in advanced wound care technology, today announced the launch of SAM™ PainGuard™ with Lidocaine, a groundbreaking addition to its acute care portfolio
Read More from Imbed Biosciences Launches Dual-Action Wound Matrix Integrating Bioburden Management and Pain Relief in a Single SolutionImbed Biosciences Announces FDA IDE Approval for Silver-Gallium Synthetic Antimicrobial Matrix Clinical Study with Human Donor Site Wounds
Investigational Device Exemption (IDE) enables Imbed’s Silver-Gallium, Ultra-Thin Matrix Technology to be tested in human clinical studies, a key step towards marketing approval Fully synthetic, bioresorbable, ultra-thin matrix with integration
Read More from Imbed Biosciences Announces FDA IDE Approval for Silver-Gallium Synthetic Antimicrobial Matrix Clinical Study with Human Donor Site WoundsImbed Biosciences Receives FDA 510(s) Clearance for Microlyte® Ag/Lidocaine
First antimicrobial wound dressing with integrated lidocaine to manage painful wounds MIDDLETON, Wis.–(BUSINESS WIRE)–Imbed Biosciences announces U.S. Food and Drug Administration 510(k) clearance to market Microlyte® Ag/Lidocaine, the first antimicrobial
Read More from Imbed Biosciences Receives FDA 510(s) Clearance for Microlyte® Ag/LidocaineImbed Biosciences, Inc awarded Skin Integrity and Wound Care agreement with Premier, Inc.
Madison Wisconsin based Imbed Biosciences, Inc has been awarded a Technology Breakthrough designation for PelashieldAM™ with Premier, Inc. through its Kiindo™ pediatric performance group and collaborative. Premier offers Breakthrough Technology designations
Read More from Imbed Biosciences, Inc awarded Skin Integrity and Wound Care agreement with Premier, Inc.Niterra Leads $10M Growth Funding Round for Imbed Biosciences
Round will fuel growth, cementing Imbed’s position as a leader in advanced wound care. SANTA CLARA, Calif.—January 8, 2024—Niterra today announced its participation in the $10M convertible debt financing for
Read More from Niterra Leads $10M Growth Funding Round for Imbed Biosciences